Drugs / NVD-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03100032 | Jan 2017 → Jan 2021 | spondylolisthesis | Novadip Biosciences | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-06-15 | Novadip Biosciences | Results Novadip Biosciences reports positive data from phase I study of NVD-001 for spinal fusion novadip.com ↗
Novadip Biosciences (“Novadip”), a clinical stage company developing treatments to regenerate impaired tissues in patients with significant unmet medical needs, today announced positive final results from a Phase I study of its autologous cell-based product, NVD- 001, in patients needing single-level spinal fusion. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-06-15 | Novadip Biosciences | Novadip Biosciences reports positive data from phase I study of NVD-001 for spinal fusion novadip.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NVD-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03100032 ↗ |
| Modality | Cell therapy | “NVD-001 is an autologous cellular medicinal product obtained by culture of adipose tissue (liposuction) leading to osteogenic cells” NCT03100032 ↗ |